Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 5.


Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue
et al (show 57 more authors) (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. LANCET, 397 (10282). pp. 1351-1362.


Gibani, Malick M, Jin, Celina, Shrestha, Sonu, Moore, Maria, Norman, Lily, Voysey, Merryn, Jones, Elizabeth, Blackwell, Luke, Thomaides-Brears, Helena, Hill, Jennifer
et al (show 15 more authors) (2020) Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model. PLOS NEGLECTED TROPICAL DISEASES, 14 (10). e0008783-.


Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 48 more authors) (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. JOURNAL OF INFECTION, 84 (6). pp. 795-813.


Munro, Alasdair PS, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate
et al (show 44 more authors) (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. LANCET, 398 (10318). pp. 2258-2276.


Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 45 more authors) (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. LANCET INFECTIOUS DISEASES, 22 (8). pp. 1131-1141.

This list was generated on Thu Sep 28 10:39:20 2023 BST.